Delivery Order SPE2DB20D9214-SPE2DB26FD4RB
- Not listed
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $14,661.00 to DMS Pharmaceutical Group Inc., a woman-owned small business (WOSB) pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of FASENRA 30 MG/ML SYRINGEML, a specialty pharmaceutical product, with a performance period running through September 5, 2024. This delivery order contract is part of a larger $499,999,999 indefinite delivery contract (IDC) that...
- This firm fixed-price delivery order worth $2,443.50 was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is for the supply of FASENRA 30 MG/ML SYRINGEML, a specialty medication, with a completion date of September 9, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $4,887.00, is for the supply of FASENRA PEN 30 MG/MLML, a pharmaceutical product. This delivery order is under a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group that has a ceiling value of up to $499,999,999 and runs through December 31, 2025. The IDC allows DLA to...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $9,774.00 to DMS Pharmaceutical Group Inc. for the supply of FASENRA 30 mg/ml syringes. The contract, which carries no set-aside designation, was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will perform all work at its facility in Park Ridge....
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $7,330.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the provision of Fasenra 30 mg/ml syringes, and is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group valued at up to $499,999,999 that runs through December 31, 2025. This IDC, under the SPE2DB program, allows the DLA to issue...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,550.00 by the Defense Logistics Agency (DLA) on September 12, 2025. The delivery order, which is scheduled for completion by October 3, 2025, covers the supply of FASENRA Pen 30 mg/mL, a prescription pharmaceutical product, with performance to take place in Conshohocken, Pennsylvania. This award was made without a...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $39,096.00 by the Defense Logistics Agency (DLA) on June 11, 2025, for the supply of Fasenra 30 mg/ml syringes. This firm fixed-price delivery order, which is expected to be completed by June 12, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a...
- DMS Pharmaceutical Group Inc. has been awarded a firm fixed price delivery order against its indefinite delivery contract with the Defense Logistics Agency to provide FASENRA 30 MG/ML SYRINGEML. The $39,096 delivery order has a completion date of October 30, 2023 and was awarded on October 27, 2023. DMS Pharmaceutical Group will supply the pharmaceutical item to DLA Troop Support Medical facilities from its place of performance in Park Ridge, Illinois. As a woman-owned small business, DMS...
- The U.S. Defense Logistics Agency (DLA) awarded a $4,887.00 firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of FASENRA 30 MG/ML SYRINGEML, a specialized pharmaceutical product, with a period of performance through November 8, 2024. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group Inc. with the DLA under the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $7,330.50, is a firm fixed-price delivery order for the supply of FASENRA 30 MG/ML SYRINGEML, a pharmaceutical product. The contract has an ultimate completion date of August 16, 2024. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with...
- SPE2DB20D9214Indefinite Delivery Contract
- SPE2DB20D9214-SPE2DB26FD4RBDelivery Order
The Defense Logistics Agency has awarded a delivery order valued at $9,774.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of FASENRA 30 mg/ml syringes. DMS Pharmaceutical Group Inc. is a critical supplier within the federal pharmaceutical supply chain and has been registered in the System for Award Management since 2001. This delivery order was issued without a set-aside designation, reflecting the company's competitive capability in unrestricted federal procurement. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of October 31, 2025, and will be performed at the company's headquarters in Park Ridge, Illinois. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy. The underlying IDC, designated SPE2DR and valued at $499,999,999, was awarded on November 13, 2025, and authorizes DLA to issue delivery orders for a comprehensive range of pharmaceutical products to support Department of Defense military healthcare facilities worldwide. The contract extends through December 31, 2036, with a 30-month base period and three 30-month option periods. DMS Pharmaceutical Group's substantial federal contracting activity and proven performance across multiple therapeutic categories position the company as a key regional pharmaceutical supplier for DoD healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.8k | 10/30/25 |